UK biotech using AI and aging clocks to discover single-gene factors that safely rejuvenate cells, led by its SB000 target.
Develops tissue-specific gene therapies that use transient partial cellular reprogramming to treat Alzheimer's and other brain diseases.
Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.
Already subscribed? Sign in →